Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (65868)	10/3/2000 12:06:39 PM
From: Aerobleu	Read Replies (1) \| Respond to of 150070

DNAP press release -- more good news! Tuesday October 3, 2000 12:27 PM Company Press Release DNAPrint Genomics, Inc. Adds Jose Arena, M.D. to Scientific Advisory Board SARASOTA, Fla.--(BUSINESS WIRE)--Oct. 3, 2000--DNAPrint genomics, Inc., (Pink Sheets:DNAP), a Sarasota based genomics company, announced today that it has added Jose Arena, M.D, Ph.D. to its Scientific Advisory Board. Dr. Arena, is currently the Director of Translational Research at the Familial Ovarian Cancer Center, Jackson Memorial Hospital and the University of Miami in Miami, Fla. Dr. Arena is also an Adjunct Associate Professor, Department of Pediatrics, Division of Genetics at the University. Dr. Arena received his M.D. in 1969 from the State University of Campinas, Campinas, SP, Brazil and has been practicing and researching medical genetics for the past 30 years. Dr. Arena holds board certification in Clinical Genetics for the American Board of Medical Genetics and was a founding fellow of the American College of Medical Genetics. From 1996 to 1998 he served as the Director of Cancer Genetics Program for the Courtelis Center for Research at the Sylvester Comprehensive Cancer Center, University of Miami Hospital. For seven years he served as the Chief of Medical Genetics Maternidade de Campinas, Campinas, SP, Brazil, and as Director for their Cytogenetics laboratory. He is also the Dean of Research at UNIBAN, (Universidad Bandeirante de Sao Paulo), Sao Paulo-Brazil. Dr. Arena has authored 11 contributions to medical genetics textbooks, has juried 42 papers on medical genetics for peer-review publication, and has himself authored 75 papers on the field. His past work encompasses a broad area of medical/clinical genetics, including work on the BRCA1/BRCA2 genes, which have been implicated in certain familial cancers. CEO/CSO Dr. Tony Frudakis said, "It is an honor to welcome Dr. Arena to our Scientific Advisory Board. His background is well suited to our interests, and his expertise in the area of medical genetics is hard to overstate." DNAP would like to take this opportunity to correct a typographical error and elaborate on the previous press release concerning Dr. Mirhashemi. Dr. Mirhashemi is currently the Medical Director and Research Coordinator, University of Miami/Jackson Memorial Hospital Familial Ovarian/Breast Cancer Center at the University of Miami, School of Medicine. In addition, he is a gynecologic oncologist, a surgeon who specializes in the treatment of women with gynecologic malignancies. His area of expertise is in ovarian, cervical, and endometrial cancers. About DNAPrint genomics DNAPrint genomics, Inc. is developing complex genetic analytics and knowledge resources for next generations personalized medicine. The company provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.dnaprint.com. For scientific inquiries please contact: Dr. Tony Frudakis at 941/351-4543. All other inquiries please contact: Richard Craig Hall at 941/341-0136. Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those contained in such statements. Factors that could cause or contribute to such differences include unexpected shortages of critical components, rescheduling or cancellation of customer orders, the timing and market acceptance of new product introductions by the Company and its competitors, and general competition and price pressures in the marketplace. -------------------------------------------------------------------------- ------ Contact: DNAPrint genomics Inc., Sarasota Scientific Inquiries: Dr. Tony Frudakis, 941/351-4543 or All other inquiries: Richard Craig Hall, 941/341-0136 Post your insight on the 'DNAprint Genomics (DNAP)' board.